Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program

Wave Life Sciences Ltd.

Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.
Wave regains full rights to WVE-003 and all HTT-targeting programs, with potential $5B-$10B commercial opportunity.
SELECT-HD clinical trial data generated significant interest from prospective partners for WVE-003.
Wave expects regulatory feedback on accelerated approval pathway for WVE-003 by end of 2024.
Cash runway unchanged into 2027, excluding potential GSK milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.